Personal MedSystems GmbH

Personal MedSystems GmbH specializes in mobile electrocardiogram (ECG) technology, providing advanced cardiac monitoring solutions designed for healthcare professionals and patients through innovative, portable devices and comprehensive services. Personal MedSystems GmbH, founded in 2008 in Frankfurt, Germany, focuses on mobile ECG technology. The company has completed two funding deals, with the latest being a Series B round in January 2017, raising EUR 5 million led by KPN Ventures. The firm is co-founded by Felix Brand and Markus Riemenschneider, with Felix Brand currently serving as CEO.

CardioSecur specializes in mobile electrocardiogram (ECG) technology, offering a core product that is a 12+ lead ECG device utilizing only four electrodes for remote applications. This innovative device is designed for ease of use and lightweight portability, allowing for comprehensive cardiac monitoring with data quality comparable to traditional systems, capturing up to 22 leads. The primary end use cases include the early detection of heart conditions such as ischemia, heart attacks, and arrhythmias, as well as preventive monitoring for individuals at risk of cardiovascular issues. CardioSecur's products are utilized by healthcare professionals, clinics, and hospitals, with a customer base that spans various geographical markets, including Europe and regions where remote healthcare solutions are increasingly in demand.

The company aims to empower both healthcare providers and patients with dependable, accessible cardiac monitoring solutions. CardioSecur generates revenue through a structured model that combines direct sales and partnerships with healthcare providers, facilitating both B2B and B2C transactions. The company's flagship products, which include the CardioSecur Pro series, are sold directly to healthcare institutions and professionals who require advanced ECG capabilities for patient monitoring. Additionally, CardioSecur may engage in subscription models for software services that accompany their devices, potentially allowing users continuous access to data analytics and remote monitoring features.

The revenue structure is designed to cater to both corporate client needs and individual consumers, ensuring a comprehensive approach to cardiac care. In January 2017, Personal MedSystems GmbH raised EUR 5 million in Series B funding to support the development of its CardioSecur mHealth platform and ECG device for monitoring cardiac symptoms. This funding will also be allocated towards expanding sales and growth efforts. The company is targeting new markets for expansion, although specific regions or timelines have not been disclosed.